Use of New GLP-1 Medicines in US Patients With and Without Alcohol Use Disorder, 2016-2024

JDW reported receiving grants from Arnold Ventures, Johnson & Johnson (through the Yale Open Data Access Project) and the FDA (through the Yale-Mayo Clinic Center for Excellence in Regulatory Science and Innovation), as well as former consulting fees from Hagen Berman Sobol Shapiro LLP and Dugan Law Firm APLC outside the submitted work. SOS reported receiving grants from the NIH during the conduct of the study; personal fees from the American Society of Clinical Psychopharmacology ACTUVE work group supported by Alkermes, Dicerna, Eli Lilly and Company, Ethypharm, Imbrium Therapeutics, Indivior, Pear Therapeutics, and Kinnov Therapeutics; nonfinancial support from Novartis (study medication), Stalicla (study medication), and Amygdala (study medication); personal fees from Dicerna; and personal fees from the University of New Mexico (consultant on NIH grant), and Indiana University (DSMB member), outside the submitted work; in addition, SOS had a patent for Mavoglurant for gambling disorder with Yale and Novartis pending and contracts with Altimmune and Tempero Bi. KJL reported receiving personal fees from UpToDate to write and edit content and other fees from Centers for Medicare and Medicaid Services Support to develop and evaluate publicly reported quality measures outside the submitted work. JSR reported receiving grants from the FDA, Arnold Ventures, Johnson & Johnson, Medical Devices Innovation Consortium, Agency for Healthcare Research and Quality, and National Heart, Lung, and Blood Institute; and having been an expert witness at the request of realtor’s attorney, the Greene Law Firm, in a qui tam lawsuit alleging violations of the False Claims Act and Anti-Kickback Statute against Biogen Inc that was Settled in September 2022. All authors report receiving funding from the National Institute on Alcohol Abuse and Alcoholism of the National Institutes of Health (1R01AA032254). The remaining authors did not have any conflicts of interest to disclose.